Suchergebnisse - "Park, Juliana"

PubPharm (20)

1

Safety and immunogenicity of a variant-adapted SARS-CoV-2 recombinant protein vaccine with AS03 adjuvant as a booster in adults primed with authorized vaccines : a phase 3, parallel-group study

enthalten in: EClinicalMedicine | 2023

von de Bruyn, G. | Wang, J. | Purvis, A. | +136

2

Ab initio calculation of the spectrum of Feshbach resonances in NaLi + Na collisions

enthalten in: arXiv.org | 2023

von Karman, T. | Gronowski, M. | Tomza, M. | +5

3

A Feshbach resonance in collisions between triplet ground-state molecules

enthalten in: Nature | 2023

von Park, J. | Lu, Y. | Jamison, A. | +2

CommentIn: Nature. 2023 Feb;614(7946):35-36. - PMID 36725989

4

Safety and immunogenicity of a variant-adapted SARS-CoV-2 recombinant protein vaccine with AS03 adjuvant as a booster in adults primed with authorized vaccines

enthalten in: bioRxiv.org | 2022

von de Bruyn, G. | Wang, J. | Purvis, A. | +35

5

Immunological non-inferiority and safety of a quadrivalent inactivated influenza vaccine versus two trivalent inactivated influenza vaccines in China : Results from two studies

enthalten in: Human vaccines & immunotherapeutics | 2022

von Liu, X. | Park, J. | Xia, S. | +12

6

Immunogenicity and safety of booster CYD-TDV dengue vaccine after alternative primary vaccination schedules in healthy individuals aged 9-50 years : a randomised, controlled, phase 2, non-inferiority study

enthalten in: The Lancet. Infectious diseases | 2022

von Coronel-Martinez, D. | Park, J. | López-Medina, E. | +14

CommentIn: Lancet Infect Dis. 2022 Jun;22(6):756-757. - PMID 35364020

7

Control of reactive collisions by quantum interference

enthalten in: Science (New York, N.Y.) | 2022

von Son, H. | Park, J. | Lu, Y. | +3

CommentIn: Science. 2022 Mar 4;375(6584):975-976. - PMID 35239362

8

Humoral and cellular immunogenicity and safety following a booster dose of a tetravalent dengue vaccine 5+ years after completion of the primary series in Singapore : 2-year follow-up of a randomized phase II, placebo-controlled trial

enthalten in: Human vaccines & immunotherapeutics | 2021

von Park, J. | Archuleta, S. | Oh, M. | +9

9

Immunogenicity and safety of simplified vaccination schedules for the CYD-TDV dengue vaccine in healthy individuals aged 9-50 years (CYD65) : a randomised, controlled, phase 2, non-inferiority study

enthalten in: The Lancet. Infectious diseases | 2021

von Coronel-MartÍnez, D. | Park, J. | López-Medina, E. | +17

10

Collisional cooling of ultracold molecules

enthalten in: Nature | 2020

von Son, H. | Park, J. | Ketterle, W. | +1